Boulder, CO — Nov. 14, 2016 ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today the issuance of the first patent for Anchored Multiplex PCR (AMP™), the technology that forms the foundation of the company’s products.
AMP is a target enrichment strategy for NGS that enables open-ended capture of target sequences from a single primer.
"With AMP, both known and novel gene fusions can be detected and novel fusion partners can be identified by NGS, a limitation of traditional opposing primer-based techniques to prepare libraries for NGS” says John Iafrate, MD, PhD, co-inventor of AMP and co-founder of ArcherDX. Furthermore, “AMP is uniquely suited for low-input sample types, such as formalin-fixed paraffin-embedded (FFPE) samples, making this technology particularly useful in clinical settings,"
Dr. Iafrate explains.
“Illumina is committed to enabling the development of companion diagnostics using NGS,” said John Leite Ph.D., Vice President of Market Development for Oncology at Illumina. “We are pleased to partner with ArcherDX to expand IVD test offerings on the MiSeqDx instrument.”
AMP was developed by Long Phi Le, MD, PhD, Zongli Zheng, PhD and Dr. Iafrate at the Massachusetts General Hospital to detect novel gene fusions in cancer. Drs. Iafrate and Le together with Jason Myers, PhD founded ArcherDX to develop and commercialize targeted NGS assays based on AMP technology. Now, the technology has proven useful to detect multiple other mutation types from both DNA and RNA extracts, allowing for comprehensive mutation profiling from a single low-input clinical specimen.
ArcherDX is rapidly expanding it’s AMP-based Archer® product line, now providing assays to detect variants in circulating tumor DNA derived from liquid biopsies (Reveal™ ctDNA 28) and to sequence the T-cell receptor repertoire (Immunoverse™ TCR), in addition to the multitude of VariantPlex™ and FusionPlex® kits that detect mutations in DNA and RNA, respectively.
The patent for AMP, U.S. Patent No. 9,487,828, was issued on November 8, 2016 to The General Hospital Corporation and is exclusively licensed to ArcherDX. This news comes just 3 years after ArcherDX was founded.
“Recognition and protection of this innovative approach to NGS-based mutation detection will foster more effective communication and collaboration for ongoing assay development and will ultimately lead to improved dissemination of AMP-based NGS assays in a variety of research areas and clinical settings,”
says Dr. Myers, CEO and co-founder of ArcherDX.
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.
By combining proprietary AMP chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
For more information, visit ArcherDX.com
Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.
2477 55th Street, Suite 202
Boulder, CO 80301